Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue supplied as a lyophilised research material. It is studied in controlled laboratory models involving the ghrelin/growth-hormone-secretagogue receptor, pituitary signalling and peptide–receptor selectivity.
Research material only
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
Compound classSynthetic pentapeptide
Reference sequenceAib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular formulaC₃₈H₄₉N₉O₅
Reference molecular mass711.9 g/mol
CAS reference170851-70-4
Research pathwayGHS-R1a / ghrelin-receptor signalling
Research context
Ipamorelin is described in the scientific literature as a growth-hormone secretagogue and agonist of the ghrelin/growth-hormone-secretagogue receptor. Early pharmacological work characterised its receptor-mediated activity and selectivity in pituitary-cell and animal models.
Additional preclinical research has examined gastrointestinal motility in postoperative animal models, while a controlled phase-two study evaluated an intravenous investigational preparation in postoperative patients. These publications describe specific experimental preparations and protocols; they do not establish the identity, purity, performance or suitability of the material supplied on this page.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the compound, vial size and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied in the vial size selected above.
- Provided as a lyophilised research material.
- Keep the vial sealed and protected from moisture, heat and direct light.
- Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.
Frequently asked questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue studied as an agonist at the ghrelin/growth-hormone-secretagogue receptor.
What does Ipamorelin interact with in research models?
Published pharmacological research primarily associates Ipamorelin with GHS-R1a, also called the ghrelin or growth-hormone-secretagogue receptor.
What is the reference sequence?
The reference sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂. The material contains non-standard residues, so simplified one-letter peptide notation does not fully describe its structure.
Which vial sizes are available?
Current selectable vial sizes and availability are shown above. These controls update automatically as variations change.
Are laboratory results available?
A shield appears beside a variation only when a published result is available. No indicator means that no product-specific result is currently displayed for that variation.
How should the material be stored?
See the Storage Guidelines tab for the current handling guidance for sealed lyophilised material and reconstituted solution.
Information reviewed 29 August 2026.
Batch-specific analytical documentation
Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.
- Result available: a published report is available for the marked variation.
- Test pending: a sample has been submitted, but no completed result is being claimed.
- No indicator: no product-specific result is currently displayed for that variation.
Check the identifiers
Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.
Browse published lab results →
Storage and stability
Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.
| Form |
Suggested storage |
Important note |
| Sealed lyophilised material |
Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. |
Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling. |
| Reconstituted solution |
Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. |
Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed. |
No universal shelf-life is claimed
Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.
Published research
The sources below concern Ipamorelin under the defined materials, routes and experimental conditions used by their authors. They provide compound-level scientific context and do not establish the identity, purity, performance or suitability of any supplied batch.
- PubChem. Ipamorelin — Compound Summary, CID 9831659. Reference structure, formula, sequence notation, identifiers and computed molecular mass. View on PubChem ↗
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. Pharmacological profiling in pituitary-cell and animal models, including growth-hormone-secretagogue receptor activity and selectivity. View on PubMed ↗
- Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, 2009. Dose and gastrointestinal-transit research in a postoperative rat model. View on PubMed ↗
- Greenwood-Van Meerveld B et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology, 2012. Gastric-emptying and smooth-muscle research in an animal model. View on PubMed ↗
- Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014. Phase-two research with an intravenous investigational preparation; the principal efficacy comparisons were not statistically significant. View on PubMed ↗
Published research is not evidence for this product
The cited findings include cell, animal and controlled clinical research using defined experimental or investigational preparations. They do not establish safety or efficacy for any use and do not establish the identity, purity or performance of the material supplied on this page. Confirm the reference structure and batch identifier against applicable analytical documentation.
